Biohaven (BHVN) Chief Scientific Officer awarded 175,000 stock options

Rhea-AI Filing Summary

Biohaven Ltd. Chief Scientific Officer Bruce Car received a grant of stock options on February 27, 2026. The award covers 175,000 stock options with an exercise price of $0.00 per share, giving him the right to buy Biohaven shares if he chooses to exercise in the future.

The options vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, and each installment requires his continuous service with the company through the relevant vesting date. After this grant, he directly holds 175,000 derivative securities in the form of stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Car Bruce

(Last) (First) (Middle)

C/O BIOHAVEN LTD.

215 CHURCH STREET

(Street)

NEW HAVEN CT 06510

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Biohaven Ltd. [ BHVN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to buy)	$11.52	02/27/2026		A		175,000		(1)	02/27/2036	Common Shares	175,000	$0	175,000	D

Explanation of Responses:

1. The shares underlying this option vest in four equal installments on February 27, 2026, 2027, 2028 and 2029, subject to the Reporting Person's continuous service with the Issuer at each vesting date.

Remarks:

	/s/ George Clark, Attorney-in-Fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Biohaven (BHVN) report for Bruce Car?

Biohaven reported a grant of 175,000 stock options to Chief Scientific Officer Bruce Car. The options were awarded on February 27, 2026 and give him the right to buy Biohaven shares in the future at an exercise price of $0.00 per share.

How many Biohaven (BHVN) stock options were granted to the Chief Scientific Officer?

Bruce Car received 175,000 Biohaven stock options in this Form 4 filing. These derivative securities increase his direct holdings to 175,000 options, vesting in four equal annual installments beginning February 27, 2026, subject to his continuous service with the company.

What is the vesting schedule of Bruce Car’s Biohaven (BHVN) stock options?

The 175,000 Biohaven stock options vest in four equal installments. Vesting dates are February 27, 2026, 2027, 2028 and 2029, and each tranche requires Bruce Car to remain in continuous service with Biohaven through the applicable vesting date.

What is the exercise price of the Biohaven (BHVN) options granted to Bruce Car?

The stock options granted to Bruce Car carry an exercise price of $0.00 per share. This means he can acquire Biohaven shares under the award without paying a cash exercise price, provided the options have vested and he satisfies all applicable conditions.

Is Bruce Car’s ownership in Biohaven (BHVN) direct or indirect after this option grant?

After the grant, Bruce Car’s 175,000 stock options are reported as directly owned. The Form 4 lists the ownership type as direct, with no footnotes indicating holding through a separate entity or disclaimers of beneficial ownership.

Does the Biohaven (BHVN) Form 4 indicate any performance conditions on Bruce Car’s options?

The filing specifies a time-based vesting schedule but no additional performance conditions. The options vest in four equal installments on specific dates from 2026 through 2029, contingent solely on Bruce Car’s continuous service with Biohaven through each vesting date.